Vasculitis & polymyalgia rheumatica
Efficacy and safety of JAK inhibitors in Behçet syndrome: systematic literature review
Authors' conclusion
This SLR showed that JAKi may be effective in refractory BS patients with a favorable safety profile.
Study context
- Population
- Patients with BD treated with JAK inhibitors (JAKi) (Embase, PubMed, Cochrane Library); mostly refractory to conventional immunosuppressives48 men
- Participants
- 92 patients
- Comparison
- Tofacitinib vs Baricitinib vs Upadacitinib
- Tofacitinibn = 46
- Baricitinibn = 31
- Upadacitinibn = 15
- Outcome
- Remission rate
Methodological detailsincludes an own case report
- Includes an own case report
Main finding
As reported in the abstract
Overall remission
85.9%
Gastrointestinal involvement remission
82.6%
Vascular involvement remission
90.9%
Eye involvement remission
84.2%
Safety
Serious adverse events
- Serious adverse events
- 5.4%
Thrombotic events
- No thrombotic events reported
Original publication
Efficacy and safety of JAK inhibitors in Behçet syndrome: systematic literature review. Semin Arthritis Rheum. Published 19 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →